NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization244.26 mln
Float38.71 mln
Earnings Date07/30/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.91
Caution advised
1-Year Forecast
8.74
Transformational upside
Relative Strength
51
/ 100
In line with market
Debt / Equity
0.14
Very low leverage
ROE
-111
Deeply negative
Business Description
AC Immune SA is a Switzerland-based clinical-stage company focused on fighting neurodegenerative diseases by targeting the misfolded proteins that drive conditions such as Alzheimer's and Parkinson's. Its two core platforms produce both biological therapies and small-molecule drugs designed to seek out and act on these harmful proteins, supporting a broad pipeline of treatments and diagnostic tools. The company works alongside major partners including Genentech, Eli Lilly, and Janssen Pharmaceuticals to advance its programs through development.
